Suspended

Specimen Analysis for Understanding Pulmonary Fibrosis

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to procure and analyze blood and tissue samples to understand pulmonary fibrosis in individuals with the condition, their family members, and healthy volunteers.

What is being collected

Data Collection

Collected at a single point in time - Cross-sectional
Who is being recruted

Albinism+27

+ Amino Acid Metabolism, Inborn Errors

+ Blood Coagulation Disorders

From 18 to 115 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: June 2004
See protocol details

Summary

Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: December 25, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: June 9, 2004

Actual date on which the first participant was enrolled.

This study aims to explore the underlying causes of pulmonary fibrosis, a lung condition with an unknown origin. Researchers are focusing on analyzing various samples from individuals diagnosed with pulmonary fibrosis, their relatives who may have hereditary links to the disease, and healthy volunteers. By examining blood, genetic material, and lung tissue obtained through procedures like bronchoscopy and biopsies, the study seeks to uncover crucial insights into how this disease develops and progresses. The findings could potentially lead to better understanding and treatment options for those affected by pulmonary fibrosis. Participants in this study will provide samples such as blood and tissue, which may be collected using different medical procedures like bronchoscopy—a procedure where a doctor looks inside the lungs with a special instrument—or through biopsies, which involve taking small samples of tissue. Some samples might also be collected after lung transplants or during post-mortem examinations. The main goal is to analyze these samples to identify patterns or abnormalities that could explain the disease. While the study involves invasive procedures, especially for those with the disease or their relatives, it holds the promise of contributing significantly to medical knowledge, potentially leading to improved diagnostics and therapies.

Official TitleAnalysis of Specimens From Individuals With Pulmonary Fibrosis 
NCT00084305
Principal SponsorNational Human Genome Research Institute (NHGRI)
Last updated: December 25, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

315 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 115 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AlbinismAmino Acid Metabolism, Inborn ErrorsBlood Coagulation DisordersBlood Platelet DisordersEye DiseasesFibrosisHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLung DiseasesMetabolic DiseasesMetabolism, Inborn ErrorsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNutritional and Metabolic DiseasesPathologic ProcessesPigmentation DisordersPlatelet Storage Pool DeficiencyPulmonary FibrosisRespiratory Tract DiseasesSkin DiseasesSkin Diseases, GeneticPathological Conditions, Signs and SymptomsEye Diseases, HereditaryAlbinism, OculocutaneousSkin and Connective Tissue DiseasesHypopigmentationLung Diseases, InterstitialHermanski-Pudlak SyndromeBlood Coagulation Disorders, InheritedGenetic Diseases, Inborn

Criteria

8 inclusion criteria required to participate
Individuals who are 18 years of age or older with any of the following:

Idiopathic pulmonary fibrosis \[defined by the American Thoracic Society/European Respiratory Society guidelines\],

Familial pulmonary fibrosis \[defined as idiopathic pulmonary fibrosis in two or more first-degree relatives\],

Relatives of patients with hereditary pulmonary fibrosis,

Show More Criteria

6 exclusion criteria prevent from participating
Individuals with any of the following:

Significant inhalational exposure to fibrogenic fibers or dusts or exposure to drugs associated with pulmonary fibrosis,

Uncontrolled ischemic heart disease,

Uncorrectable bleeding diathesis,

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

National Institutes of Health Clinical Center

Bethesda, United StatesSee the location
SuspendedOne Study Center